By Cecilia Butini

 

Bayer AG said Tuesday that it has entered into a development-and-license agreement with U.K.-based company Blackford Analysis Ltd. to build a digital platform for medical imaging.

Under the agreement, Bayer will create artificial intelligence-enabled solutions to power the platform, which should allow health-care professionals to manage digital-clinical imaging. The platform will provide access to diagnostic imaging analysis applications, protocol management tools and AI algorithms, giving physicians the potential to increase efficiency and reduce errors, the German chemical and pharmaceutical conglomerate said.

Blackford Analysis will provide the underlying technology for Bayer to develop its digital solutions, it added.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

December 01, 2020 10:13 ET (15:13 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Bayer